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Abstract
Background: EGb761, a standardized Ginkgo biloba extract, has antioxidant and antiplatelet aggregation and thus might
protect against atherosclerosis. However, molecular and functional properties of EGb761 and its major subcomponents
have not been well characterized. We investigated the effect of EGb761 and its major subcomponents (bilobalide,
kaemferol, and quercetin) on preventing atherosclerosis in vitro, and in a rat model of type 2 diabetes.
Methods and Results: EGb761 (100 and 200 mg/kg) or normal saline (control) were administered to Otsuka Long-Evans
Tokushima Fatty rats, an obese insulin-resistant rat model, for 6 weeks (from 3 weeks before to 3 weeks after carotid artery
injury). Immunohistochemical staining was performed to investigate cell proliferation and apoptosis in the injured arteries.
Cell migration, caspase-3 activity and DNA fragmentation, monocyte adhesion, and ICAM-1/VCAM-1 levels were explored in
vitro. Treatment with EGb761 dose-dependently reduced intima-media ratio, proliferation of vascular smooth muscle cells
(VSMCs) and induced greater apoptosis than the controls. Proliferation and migration of VSMCs in vitro were also decreased
by the treatment of EGb761. Glucose homeostasis and circulating adiponectin levels were improved, and plasma hsCRP
concentrations were decreased in the treatment groups. Caspase-3 activity and DNA fragmentation increased while
monocyte adhesion and ICAM-1/VCAM-1 levels decreased significantly. Among subcomponents of EGb761, kaemferol and
quercetin reduced VSMC migration and increased caspase activity.
Conclusions: EGb761 has a protective role in the development of atherosclerosis and is a potential therapeutic agent for
preventing atherosclerosis.
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Introduction
Ginkgo biloba L. (Ginkgoaceae), known as the ‘maidenhair tree’, is
the best-selling herbal remedy in the USA [1]. Traditionally, the
fruits and seeds of Ginkgo have been used in Oriental medicine to
improve chronic cough or enuresis [2]. Since the early 1990s,
EGb761, a standardized extract of Ginkgo leaves, has become the
most popularly used dietary supplement for treating vascular
circulation problems and improving memory.
There are two major fractions in this extract: flavonoids and
terpenes. Interestingly, these two have different properties which
are responsible for exerting unique and diverse pharmacological
actions of EGb761. The flavonoid fraction has antioxidant effects
resulting from direct attenuation of reactive oxygen species by
chelating pro-oxidant transitional metal ions, and also by
promoting the expression of antioxidant proteins which in turn
increases antioxidant metabolites such as glutathione [3–5]. The
chemical structure of flavonoids comprising of an aromatic ring
and a double bond seem to react preferentially with hydroxyl
radicals [2]. The terpene lactones include the ginkgolides A, B, C,
J and M, and bilobalide [6]. These were found to reduce platelet
activation and aggregation by antagonizing platelet activating
factor [7,8]. This gives EGb761 the potential to improve blood
circulation. In addition, bilobalide, a sesquiterpene trilactone, was
shown to reduce cerebral edema, cortical infarct volume and
ischemic damage in patients following a stroke [9].
EGb761 has also been shown to have various antiapoptotic
properties[6] and to inhibit amyloid-beta aggregation [10].
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peripheral vascular insufficiency, to protect against neurological
disorders such as ischemic injury and to treat cerebral disorders
such as cognitive decline and memory impairment [9].
Interestingly, in addition to its neurological and vascular
protective effects, EGb761 has been reported to reduce hypergly-
cemia. Rapin et al. reported that EGb761 increased glucose
uptake and glycogen synthesis, and Tanaka et al. showed that the
glucose-lowering effect of Ginkgo extracts was caused by the
inhibition of alpha-amylase and glucosidase [11,12].
Although EGb761 has beneficial effects on blood circulation
and hyperglycemia in patients with diabetes, direct studies on its
effects against atherosclerosis are limited. Therefore, we investi-
gated the protective effect of EGb761 on atherosclerosis in a rat
model of obese type 2 diabetes. We also examined the possible role
of EGb761 and its major subcomponents on the development and
progression of atherosclerosis in vitro. In addition, the effects of
EGb761 on glucose homeostasis, circulating adipocytokines and
inflammatory markers were evaluated.
Materials and Methods
Animal and Material
Thirty-six 5-week-old male Otsuka Long-Evans Tokushima
Fatty (OLETF) rats were donated by the Otsuka Pharmaceutical
Co. (Tokushima, Japan). They were allowed to grow to 24 weeks
of age, when obesity and insulin resistance develop. The OLETF
rats were held in the Preclinical Laboratory of Seoul National
University Bundang Hospital, South Korea, for the study
duration. All animals were handled in compliance with the Guide
for Experimental Animal Research of the Laboratory, Seoul
National University Bundang Hospital. Seoul National University
Bundang Hospital Ethics Committee for Animal Study approved
this study (06-2008-096).
We divided the rats into three groups (n=12 each) and treated
them as follows: controls (5 ml normal saline per day), rats given
100 mg/kg of EGb761 per day (EGb100), and rats given 200 mg/
kg of EGb761 per day (EGb200). All rats were fed a regular chow
diet and had free access to water. EGb761 or normal saline were
administered using an oral Zonde needle (Natsume, Tokyo, Japan)
at 9–10 am for 6 weeks (from 3 weeks before to 3 weeks after
balloon injury). EGb761 was supplied by Dr. Willmar Schwabe
Pharmaceuticals (KG, Karlsruhe, Germany). Two major ingredi-
ents were ginkgo flavone glycoside (24.31%) and terpene
trilactones (5.42%). Subcompounds of EGb761 are described in
Table S1.
Additional experiments were carried out involving male
ApoE-/- mice (n=12) 5 weeks of age, which were purchased
from Jackson laboratories (Bar Harbor, Maine). For 2 months all
mice were fed high fat cholesterol diet #88137 (Harlan-Teklad;
42% fat, 1.25% cholesterol) beginning at 5 weeks of age. After 2
months, mice were divided into three groups: control, EGb100
and EGb200 (n=4 each) and continued on the high fat diet. Mice
were sacrificed after 2 months post treatment to evaluate the
degree of plaque formation. Whole aortas were opened lengthwise,
fixed in 10% formalin, stained with oil red O and quantified by
computerized morphometrics. The results for atherosclerotic
plaque were expressed as the mean6standard error of the mean.
Rat carotid artery balloon denudation injury and
morphometric analysis
Balloon injury of the carotid artery was performed according to
a well-established injury model [13]. The extent of neointimal
formation in histologically stained sections was quantified by
computed planimetry. The cross-sectional areas of the blood vessel
layers (i.e., the lumen, intimal, and medial areas) were quantified
in three different sections (proximal, middle, and distal) using
Image-Pro Plus Analyzer version 4.5 (Media Cybernetics,
Bethesda, MD, USA). The intima to media ratio (IMR) was
calculated from the mean of these determinations.
Immunohistochemical staining for proliferating cells and
inflammatory cells
To detect proliferating cells, immunohistochemical staining for
proliferating cell nuclear antigen (PCNA) was performed, as
previously described [14]. The proliferation index was defined as
the percentage of PCNA-positive cells relative to the total
nucleated cell count in four different sectors per tissue section.
Staining for the glycoprotein ED-1 (Dako, Carpinteria, CA,
USA), which is expressed predominantly on the lysosomal
membrane of tissue macrophages, was performed on the injured
carotid arteries.
Staining for Apoptosis
Detection of apoptotic cells in vivo was also performed using the
terminal deoxynucleotidyl transferase-mediated dUTP nick and
labeling (TUNEL) method with minor modification [15]. Briefly,
5 mm sections were deparaffinized and incubated with proteinase
K (Dako) (20 mg/ml) for 15 min at room temperature. An
apoptosis detection kit (Apoptag, Intergen Company, Purchase,
NY) was used with the chromogen DAB. Sections were
counterstained with Mayer’s hematoxylin (Dako). Apoptotic cells
were quantified by determining the percentages of TUNEL-
positive cells among all nucleated cells counted in four different
sectors per tissue section.
Glucose Metabolism, Adipocytokine and Inflammatory
Markers
Possible relevant factors affecting the degree of neointimal
formation, such as glucose homeostasis, adipocytokines and
inflammatory status were evaluated. To assess glucose homeosta-
sis, an intraperitoneal glucose tolerance test (IPGTT) was
performed at baseline and 6 weeks after the EGb761 treatment.
Rat adiponectin, high-sensitivity C-reactive protein (hsCRP),
monocyte chemoattractant protein-1 (MCP1), TNFa and plas-
minogen activator inhibitor-1 (PAI1) activity were measured using
commercial kits.
Cell Culture
Rat aortic smooth muscle cells (RAoSMCs; Bio-bud Seoul,
Korea) and human umbilical vein endothelial cells (HUVECs;
Cambrex, Walkersville, MD) were used for in vitro experiments.
See the Table S1 and Figures S1, S2, S3, S4, S5, S6 for detailed
information.
Cell Proliferation and Cytotoxicity
Effects of EGb761 on RAoSMCs proliferation was determined
by a modified 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT) assay. To investigate cell viability of
EGb761, calcein-acetoxymethyl ester (calcein-AM) cell viability
assay kit was used (Biotium, Hayward, CA, USA).
Cell Migration
RAoSMCs were grown to confluence in 6-well plates (SonicSeal
Slide Wells, Nalge Nunc, Rochester, NY) and then starved in
DMEM with 0.5% FBS for 48 h. Thereafter, each well was
divided into a 263 grid. Using 100-1000 mL pipette tips, a linear
Effect of EGb761 on Atherosclerosis
PLoS ONE | www.plosone.org 2 June 2011 | Volume 6 | Issue 6 | e20301Figure 1. In vivo inhibition of neointimal formation after 6 weeks of treatment with EGb761. A. H&E stained sections of the three groups.
B. Intima to media ratios (IMRs) in the three groups (n=10 in each group). Treatment with EGb761 produced a lower IMR than controls in a dose-
dependent manner (the lower IMR with the higher dose of EGb761, p,0.05). C. Representative examples of aortas from ApoE-/- mice stained en-face
with Oil-Red. Red color indicates the aortic arch where plaque accumulation is the highest. D. Quantification of aortic arch plaque in the three groups
expressed as the mean6SEM percent. A dose-dependent decreased plaque volume was found in the EGb groups.
doi:10.1371/journal.pone.0020301.g001
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after this, the medium was replenished with starvation medium.
TNFa (10 ng/ml) was mixed in starvation medium. Cells were
allowed to migrate for 24 h at 37uC. Images were taken of the
intersections of the linear wound and each grid line, which resulted
in 3 fields per well.
Figure 2. Effects of EGb761 (100 or 200 mg/kg) treatment or normal saline (control) on the proliferation and apoptosis of vascular
smooth muscle cells. A. Cell proliferation measured by immunostaining for proliferating cell nuclear antigen (PCNA) was markedly lower in the
EGb761-treated groups than in the controls (open arrow). B. The proliferation index was significantly lower in the EGb761-treated groups than in the
control group. There was a dose-dependent pattern in the level of proliferation between EGb761-treated groups (* p,0.05 vs. control and {
p,0.05 vs. EGb100). C. TUNEL staining of the three groups (open arrow). D. Apoptosis index (%) at 3 weeks after balloon injury. Apoptosis was
significantly higher in the EGb761-treated groups than in the control group, and there was a dose-dependent pattern in the level of apoptosis
between EGb761-treated groups (* p,0.05 vs. control and { p,0.05 vs. EGb100).
doi:10.1371/journal.pone.0020301.g002
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U937 cells (Human leukemic monocyte lymphoma cell line;
Abcam, Cambridge, MA) were washed 3 times with serum-free
RPMI medium and then resuspended in the same medium. The
U937 cells (1.25610
4) were added to the HUVEC monolayers
stimulated with TNFa (10 ng/ml) for 18 h and incubated for
30 min at 37uC under 5% CO2 in air. Unbound cells were
removed by washing 3 times with PBS. EBM-2 medium was then
added and all U937 cells adhering to an endothelial cell were
counted in 3–5 randomly selected fields of view in each well using
a phase-contrast microscope.
Intercellular Adhesion Molecule (ICAM) and Vascular Cell
Adhesion Molecule (VCAM)
For reverse transcription–polymerase chain reaction (RT-PCR),
RNA was isolated from HUVECs according to the TRIZOL
protocol (Gibco Life Technology). Primer and probe sequences for
ICAM and VCAM were described previously [16]. The RT-PCR
was performed with the TaqMan system (Prism 7700 Sequence
Detection System, PE Biosystems, Foster City, CA). Thermal
cycling conditions comprised an initial denaturation step at 94uC
for 5 min, followed by 94uC for 30 sec, 58uC for 60 sec, and 72 for
30 sec for 40 cycles. For quantification, the target sequences were
normalized in relation to the human GAPDH product (Clonetech,
Heidelberg, Germany).
Immunoblot Analysis for Caspase-3 Activity
Immunoblot analysis was performed with primary antibodies
directed against pro-caspase-3; cleaved caspase-3; b-actin (all from
Santa Cruz Biotechnology). The bands were visualized with
enhanced chemiluminescence and quantified by densitometry.
Cleaved caspase 3-expression data were normalized by b-actin
levels.
DNA fragmentation
DNA fragmentation, a distinctive feature of apoptosis at the
biochemical level, was evaluated with EGb761 (100 and 200 mg/
ml) and its subcomponents; kaemferol, quercetin and bilobalide
(10, 20 and 50 mg/ml, respectively).
Statistical Analysis
Results are reported as the mean6standard error (SE). Mean
values were compared for the EGb761-treated groups and control
group by ANOVA with a post hoc test and p,0.05 was
considered statistically significant. Analysis was done using SPSS
for Windows version 11.0 (SPSS Inc., Chicago, IL).
Results
In vivo Inhibition of Neointimal Formation and Plaque
Development
Three weeks after injury, the EGb761-treated groups showed a
significant reduction in neointimal formation compared to the
control group (Fig. 1A). The EGb200 group showed less
neointimal formation than the EGb100 group (Fig. 1A, B). As
shown in Fig. 1B, there was a dose-dependent reduction of the
IMR between the two EGb761-treated groups (Control,
1.4060.20; EGb100, 0.9060.14; EGb200, 0.4360.09, p,0.05).
Representative examples of aortas from ApoE-/- mice stained en-
face with Oil-Red are shown in Fig. 1C. Red color indicates the
aortic arch where plaque accumulation is the highest. Fig. 1D
shows the quantification of aortic arch plaque in the three groups
Figure 3. Effects of EGb761 on proliferation and TNFa-stimulated migration of rat aortic smooth muscle cells (RAoSMC). A. In MTT
viability assays, cell proliferation was significantly decreased in a dose dependent manner by EGb761 treatment (* p,0.05 and ** p,0.01 compared
with untreated RAoSMC). B. Measurement of cell migration assessed by wound healing assay. C. Quantification of the migration distance as a
percentage of the control value (** p,0.01 compared with TNFa only treatment).
doi:10.1371/journal.pone.0020301.g003
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decreased plaque volume was found in the EGb groups.
Inhibited Proliferation and Sustained Apoptosis of
Vascular Smooth Muscle Cells and Reduced Inflammatory
Cells
Cell proliferation and apoptosis are important contributors to
neointimal formation after balloon injury. We performed experi-
ments investigating the role of EGb761 in reducing proliferation and
promoting apoptosis of cells. As shown in Fig. 2A, the proliferative
index was significantly lower in the EGb761 treated groups than in
the control (control, 16.864.1%; EGb100, 12.762.1%; EGb200,
8.263.2%, p,0.05 vs. control, respectively). There was a dose-
dependent decrease in proliferation between the two EGb761-treated
groups (p,0.05) (Fig. 2B). At 3 weeks after injury, the apoptosis
index was significantly higher in the EGb761-treated groups than in
the control group (Fig. 2C). There was also a dose-dependent
increase in the level of apoptosis between the two EGb761 groups
(control 6.960.6%; EGb100, 11.060.6%; EGb200, 20.461.9%,
p,0.05) (Fig. 2D). Immunohistochemical staining for ED-1 (an
inflammatory cell marker in the rat) in the injured carotid vessel wall
alsoshowed that ED-1 positivecells were more frequentin the control
group than in the EGb761-treated groups (Fig. S1).
Decrease in Proliferation and TNFa-directed Migration of
RAoSMCs
As shown in Fig. 3A, EGb761 treatment inhibited proliferation
of RAoSMCs. This effect was initiated at 50 mg/ml of EGb761
and was increased dose-dependently to 200 mg/ml. This anti-
proliferative property of EGb761 did not induce cytotoxicity, as
shown by the results of the calcein measurement (Fig. S2).
EGb761 treatment also inhibited platelet-derived growth factor
(PDGF)-stimulated RAoSMC proliferation (Fig. S3). Further-
more, EGb761 treatment inhibited TNFa-directed migration in
rat RAoSMCs dose-dependently (Fig. 3B, C). When subcom-
pounds of EGb761 were used, kaemferol and quercetin inhibited
TNFa-directed RAoSMC migration while bilobalide showed no
change (Fig. S4).
Decrease in Monocyte Adhesion
The adhesion of inflammatory cells has a critical role in the
development of atherosclerosis. Increased monocyte adhesion was
Figure 4. Effect of EGb761 on monocyte adhesion and adhesion molecule expression. A. EGb761 treatment reduced TNFa-stimulated
monocyte adhesion using U937 cells (Open arrows indicate adhered monocytes). B. Monocyte adhesion rate as a percentage of the control value
(** p,0.01 compared with TNFa only treated group). C and D. ICAM and VCAM expression levels in human umbilical vein endothelial cells. (* p,0.05
and ** p,0.01 compared with TNFa treatment).
doi:10.1371/journal.pone.0020301.g004
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adhesion assay (Fig. 4A). As shown in Fig. 4B, EGb761 treatment
significantly and dose-dependently decreased monocyte adhesion.
Effect of EGb761 on ICAM and VCAM Expression in
HUVECs
Adhesion molecules such as ICAM and VCAM are also
involved in the development of restenosis. In this study, expression
of ICAM and VCAM were significantly decreased by treatment
with EGb761 at both 100 and 200 mg/ml (Fig. 4C and 4D).
Caspase-3 Activity and DNA fragmentation
Apoptosis of cells is an important contributor to neointimal
formation inhibition. To evaluate effect of EGb761 and its
subcompounds on apoptosis in vitro, caspase-3 activity and DNA
fragmentation assay were used. EGb761 treatment increased the
level of cleaved caspase-3, reflecting apoptosis in RAoSMCs
(Fig. 5A and 5B). Treatment of kaemferol or quercetin also
increased caspase activity significantly (Fig. S5). Treatment of
kaemferol, quercetin and EGb761 increased DNA fragmentation
compared to control group. Subcompound bilobalide also did not
increase DNA fragmentation (Fig. 5C).
Effect of EGb761 Treatment on Glucose Metabolism,
Plasma Adiponectin and Inflammatory Markers
After 6 weeks of treatment with EGb761, significant improve-
ment of postload glucose excursion was found in both EGb100
and EGb200 groups compared with control (Table 1). Further-
more, EGb761 treatment increased plasma adiponectin concen-
trations and decreased hsCRP concentrations (Table 1). Although
the EGb761-treated groups showed lower fasting insulin levels and
HOMA-IR than controls, these were not statistically significant.
Similarly, the levels of other inflammatory markers such as MCP1,
TNFa and PAI1 were lower in EGb761-treated rats than in
controls, but these were not statistically significant.
Discussion
Six weeks of treatment with EGb761, a standardized Gingko
biloba extract, produced significantly less neointimal formation in
balloon injured carotid arteries than in the control group in a dose-
dependent manner (35.5% in the EGb100 group and 69.3% in
EGb200) which was accompanied by reduced proliferation and
increased apoptosis of vascular smooth muscle cells (VSMCs).
EGb761 treatment also showed anti-atherosclerotic effects in vitro.
It decreased proliferation and migration, and increased apoptosis
of VSMCs. It also decreased monocyte adhesion and levels of
adhesion molecules in HUVECs. Among subcomponents of
EGb761, kaemferol and quercetin played a major role in the
prevention of atherosclerosis.
The proliferation and migration of VSMCs are important
contributors to neointimal formation after balloon injury [17,18].
Apoptosis is also important in this process [19]. Therefore, prior
efforts to reduce the extent of restenosis have focused on various
interventions that reduced the proliferation and migration of
VSMCs or of increased their apoptosis [19,20]. EGb761 has
antioxidant, anti-inflammatory and anti-platelet aggregation
effects [2,5–7,9,10]. In our study, EGb761 also increased
caspase-3 activity in VSMCs. It is known that EGb761 has anti-
Figure 5. Effect of EGb761 on apoptosis. A. Induction of apoptosis shown by the activation of caspase-3 with EGb761 treatment. B. Dose-
dependent increasing pattern of caspase-3 activity by EGb761 (**p,0.05 compared with TNFa only treatment). C. DNA fragmentation by bilobalide,
kaemferol, quercetin and EGb761.
doi:10.1371/journal.pone.0020301.g005
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EGb761 may also have different effects on cell survival under
specific conditions such as target cells and the dosage used. Several
studies showed that EGb761 had proapoptotic effects in high
turnover state such as cancer [21–23]. Thus, EGb761 could
have proapoptotic effects on VSMCs in the development of
atherosclerosis.
It is well known that infiltration of inflammatory cells occur
early after endothelial denudation [24–27] and its inhibition is
associated with a reduction in medial VSMC proliferation [24].
These data suggest a central role of inflammatory cells in restenosis
and provide insights as to how EGb761 might reduce neointimal
growth in arteries after balloon injury. Based on previous studies
showing a linear relationship between tissue monocyte content and
neointimal area [27] and decreased neointimal thickening through
blocking early monocyte recruitment by anti-inflammatory drugs
[28], inflammatory responses related with monocyte infiltration
might aggravate restenosis.
In this study, EGb761 significantly and dose-dependently
reduced the levels of adhesion molecules and the degree of
monocyte adhesion. These findings could explain the beneficial
effects of EGb761 on preventing atherosclerosis as such infiltra-
tions of inflammatory cells promote an atherosclerotic milieu
[18,25,29].
There have been several reports showing that EGb761 improves
glucose homeostasis [30,31]. A recent study proved that EGb761
induced insulin secretion and that this was mediated by increased
intracellular calcium transients [30]. Another group reported that
EGb761 ingestion increased plasma insulin levels in response to
oral glucose loading in subjects with type 2 diabetes [31]. These
data thus suggest that EGb761 enhances pancreatic beta cell
function. Consistent with these studies, the AUCglucose calculated
from the IPGTT in our study was decreased slightly but
significantly in EGb761-treated groups compared with controls.
This improved glucose excursion might also contribute to
decreased restenosis, although there is no clear explanation for
the lack of a dose-dependent response.
Other possible relevant factors affecting the degree of neointimal
formation were also evaluated in this study. Circulating levels of
adiponectin were increased significantly in EGb761 treatment in a
dose-dependent manner. Adiponectin has attracted considerable
attention recently as an adipokine that may have critical roles in the
development of atherosclerosis [32]. Importantly, low adiponectin
level is a risk factor for the subsequent development of cardiovascular
diseases [33–37]. Adiponectin directly stimulates NO production
from endothelium viaactivation of AMP-activated proteinkinase and
eNO synthase [38]. Therefore, increasing adiponectin levels are
predicted to improve both insulin sensitivity and endothelial function
by multiple mechanisms [39]. In this study, there was a negative
correlation between adiponectin and TNFa concentration
(r=20.369, P=0.027), although TNFa levels were not significantly
decreased by EGb761 treatment. This data suggests that reducing
restenosis by EGb761 treatment may be mediated by increased
adiponectin with decreased TNFa level. In addition, hsCRP, an
inflammatory marker, was significantly decreased by EGb761
treatment in this study. Many types and levels of association between
hsCRP and atherosclerosis or cardiovascular diseases have been
suggested [29,40–43]. The associations confirm that atherosclerosis
and insulin resistance share a common inflammatory basis by
demonstrating that hsCRP has direct harmful effects on vessel walls
Table 1. Weight, Biochemical Parameters, Insulin Resistance Index and Inflammatory Markers in Obese Rat Model of Type 2
Diabetes at the End of 6 Weeks of EGb761 Treatment.
Control (n=10) EGb100 (n=10) EGb200 (n=10) P Value{
Mean SD Mean SD Mean SD
Weight, g 583.1 29.3 576.3 27.5 575.5 33.8
Liver weight, g 3.30 0.65 3.03 0.26 2.98 0.22
White adipose fat weight, g 1.35 0.21 1.27 0.16 1.29 0.20
Fasting glucose, mg/dl 119.6 12.6 117.2 8.6 116.2 11.8
2h postload glucose, mg/dl 204.9 28.0 168.8 27.2 169.4 15.8 A,B
AUCglucose 808.5 45.7 659.0 66.3 703.7 66.7 A,B
Fasting insulin, pg/ml 182.6 106.7 177.6 79.9 168.6 90.9
Total cholesterol, mg/dl 82.6 15.3 81.9 12.9 77.6 9.9
Triglyceride, mg/dl 60.5 21.9 58.4 26.9 48.7 17.2
HDL-cholesterol, mg/dl 23.5 4.1 23.2 4.3 22.9 2.2
LDL-cholesterol, mg/dl 47.0 12.0 47.0 12.5 44.9 8.9
MCP1, pg/ml 195.5 67.5 160.5 53.0 179.9 75.6
TNFa, pg/ml 8.5 3.3 6.2 3.2 6.1 2.3
PAI1, pg/ml 313.1 162.0 212.0 82.9 259.6 108.7
Adiponectin, mg/ml 10.6 2.4 11.1 3.6 14.5 4.3 A,B
HsCRP, mg/l 0.19 0.04 0.16 0.02 0.15 0.03 A,B
HOMA-IR 55.3 34.2 51.2 24.0 47.4 26.5
HOMA-B 1162.0 713.4 1228.1 607.5 1230.9 647.0
Key: AUCglucose, Area under the curve of glucose; HOMA-IR, homeostasis model assessment of insulin resistance; HOMA-B, homeostasis model assessment of beta cell
function.
{ANOVA with post hoc test (Tukey’s-b) was used (A, B and C; mean significant difference between two groups: A=Control vs. EGb100, B=Control vs. EGb200,
C=EGb100 vs. EGb200, p,0.05 in all cases).
doi:10.1371/journal.pone.0020301.t001
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administration of proinflammatory cytokines impaired endothelium-
dependent vascular relaxation [40]. Collectively, hsCRP has
proatherogenic and prothrombic properties [44], which include its
interaction with LDL-cholesterol [41] and complement-CRP
complexes [43], and its capacity to stimulate tissue factor production
by macrophages [42]. Furthermore, cytokines produced by adipo-
cytes, such as IL-1, IL-6, and TNFa, stimulate the hepatic synthesis of
CRP [45] and modify glucose and lipid metabolism [46]. Thus, the
systemic acute phase response might mediate systemic metabolic
impairments and induce atherosclerosis.
EGb761 exerts inconsistent effects on lipid metabolism despite its
well known beneficial effects on insulin sensitivity. In our study,
treatment of EGb761 did not ameliorate lipid profiles. Our finding
is consistent with 2 clinical studies showing that EGb761 treatment
did not change lipid profiles in subjects with highcardiovascular risk
[47,48]. In contrast, a study involving rats indicated that EGb761
treatment improved lipid profiles [49] and another study reported
that Ginkgo biloba extracts reduced lipid peroxidation and scavenged
lipid radicals in vivo [50]. Thus, based on the inconsistency of
evidence, further study is needed to clarify the role of EGb761 on
lipid metabolism. In this study, effect of EGb761 on blood pressure
was also measured. There were no significant differences in systolic
blood pressure between angiotensin II only and angiotensin
II+EGb761 treated rats, although decreasing trend could be seen
in angiotensin II+EGb761-treatment groups (Fig. S6).
Recently, Liu F et al observed that Ginkgo biloba extract decreased
homocysteine-induced intimal thickening after balloon injury in
rabbit abdominal aorta [51]. They suggested that the mechanism
was possibly associated with the suppression of MMP-9 expression
and increased endogenous p21 expression by Ginkgo biloba extract.
However, the authors did not provide direct effects of Ginkgo biloba
extract on SMC proliferation or migration in vivo or in vitro.W e
therefore used comprehensive methods to investigate the direct
mechanism of action of EGb761, various biochemical parameters
including adiponectin, hsCRP and other cytokines, monocyte
adhesion, apoptosis as well as immunohistochemical staining for
proliferatingand apoptotic cells inthe injured vessels of obese type2
diabetic animals. In addition, we further investigated the effects of
major subcompounds of EGb761 to identify specific components
responsible for preventing restenosis.
In conclusion, treatment with EGb761 was found to reduce
restenosis in obese rats with type 2 diabetes after balloon injury to
the carotid artery. EGb761 significantly suppressed the prolifer-
ation and migration of VSMCs, promoted apoptosis and reduced
inflammatory processes. In addition, EGb761 showed favorable
effects on glucose homeostasis and on adiponectin and hsCRP
levels. Among subcomponents of EGb761, kaemferol and
quercetin seem to play a major role in the prevention of
atherosclerosis. These findings support an emerging role of
EGb761 in reducing cardiometabolic risks. Specific intervention
studies are needed to confirm the positive effects of EGb761 in
type 2 diabetic patients.
Supporting Information
Figure S1 Immunohistochemical staining of ED-1 in the injured
carotid vessel wall I. Arrows indicate ED-1 positive cells in the
representative examples. II. Quantification of ED-1 positive cells
among control, EGb100 and EGb200.
(TIF)
Figure S2 Effect of EGb761 (a) and its subcompounds
(bilobalide, kaemferol and quercetin) (b) on cell survival with
calcein measurement.
(TIF)
Figure S3 Effect of EGb761 on PDGF-induced RAoSMC
proliferation (** p,0.01 compared with PDGF only treatment).
(TIF)
Figure S4 Effect of EGb 761 subcompounds on migration of
RAoSMC by wound-healing assay (a). Quantification of the
migration distance as a percentage of the control value (b) (**
p,0.01 compared with TNFa only treatment).
(TIF)
Figure S5 Measurement of caspase activity by treatment of
subcompound of EGb761 (kaemferol, quercetin, and bilobalide)
(**p,0.01 compared with TNFa only treatment).
(TIF)
Figure S6 Effect of EGb761 (200 mg/kg) or candesartan (4 mg/
kg) on blood pressure in OLETF rats. Angiotensin II (ATII) was
used to increase blood pressure (*p,0.01, ATII only vs.
ATII+Candesartan).
(TIF)
Table S1 Component of EGb761.
(DOC)
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